Data protection Impressum

R&D

Oculis, the Lausanne-based biopharmaceutical company focused on ophthalmology and neuro-ophthalmology, will acquire all worldwide development and commercial rights to Privosegtor from Accure, terminating its existing license agreement.

Oculis acquires worldwide rights to its Privosegtor candidate

17 August 2026

Researchers at EPFL, with colleagues from the University of Geneva, Geneva University Hospitals and Zurich, have developed VirTues, an AI foundation model for tissue biology that analyzes tumor tissue across many cancer types, with results published in Nature.

EPFL’s VirTues AI model maps tumor tissue across cancer types

17 August 2026

LS Instruments, a Fribourg-based maker of advanced light scattering and microrheology instruments, has been acquired by Germany's Postnova Analytics, with operations, manufacturing and the existing team remaining at its Fribourg headquarters.

LS Instruments joins Postnova Analytics while keeping its operations in Fribourg

12 August 2026

AB2 Bio has received a USD 30 million payment after Japanese pharmaceutical company Nippon Shinyaku exercised its option to commercialize Tadekinig alfa in the United States, with up to USD 600 million in further milestone and royalty payments.

AB2 Bio receives USD 30 million as Nippon Shinyaku takes up US rights

3 August 2026

Actival, a CSEM spin-off based in Neuchâtel, has been awarded a CHF 1.4 million grant from Innosuisse to accelerate the development and market launch of its patented Active Splints, a new generation of dental aligners that dispense antibacterial fluid and fluoride.

Actival secures a CHF 1.4 million Innosuisse grant for its smart dental aligners

3 August 2026

MoleSense and Impli, both based at the Biopôle life sciences campus, have been selected by Germany's Federal Agency for Breakthrough Innovation to develop biosensors capable of continuously measuring at least four hormones over seven days.

MoleSense and Impli selected for the SPRIND Challenge on continuous hormone monitoring

3 August 2026

Immitra Bio, based in Plan-les-Ouates in the canton of Geneva, has closed an upsized CHF 2.4 million pre-seed round to advance its scalable in-vivo gene editing platform and its lead candidate for an inherited anemia.

Immitra Bio raises CHF 2.4 million to advance its in-vivo gene editing platform

3 August 2026

SWISSto12, the Renens-based space technology company and EPFL spin-off, has closed a USD 70 million Series C round to meet growing demand for its payloads and satellites across multiple orbits.

SWISSto12 raises USD 70 million to meet growing multi-orbit satellite demand

16 July 2026

Bearmind, a Lausanne-based sports-tech start-up, has been named one of eleven winners of the 2026 WIPO Global Awards, taking the Sport category from a field of more than 1,300 applicants across 126 countries.

Lausanne’s Bearmind wins the Sport category at the 2026 WIPO Global Awards

13 July 2026

Neur.on, the Fribourg-based LegalTech behind the AI legal translation platform Corrext, has joined forces with Legal 230, Europe's leading legal translation network, while preserving Swiss data hosting and its Fribourg team.

Fribourg LegalTech Neur.on partners with European leader Legal 230

8 July 2026

1 2 3 4 5 6 … 17